TCL Archive Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events June 28, 2013
TCL Archive Xeloda, Taxotere, Herceptin Combination May Benefit Invasive Breast Cancer January 25, 2008
TCL Archive Opening Shots Fired In 10 Year Defense of Cancer Program, Launching Of Effort To Continue, Expand It September 19, 1980
TCL Archive Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone April 10, 1987
